Wuhan General Group appoints Michael Sachar CEO of M2Bio Sciences Food & Beverage

CAPE TOWN, SA / ACCESSWIRE / May 20, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company specializing in alternative medical research into plant cannabinoids and psilocybin, is pleased to share the following update:

The company is pleased to announce the appointment of Michael sachar as CEO of M2Bio Sciences Food and Beverage. Michael brings with him 17 years of exclusive and extraordinary knowledge of the food and beverage industry and a cargo of wisdom and success. Michael is the husband of a remarkable wife and the very proud father of two wonderful children. Michael has worked in many countries around the world and is now based full time in Cape Town, South Africa.

“Our first priority was to find the right candidate to lead M2Bio Sciences Food and Beverage. It was imperative that the candidate demonstrate phenomenal leadership abilities, high intensity and resilience, empathy for others and love for science and food. Michael checked the box for all and many more. We are very happy and lucky to see him join the family. “ mentionned Wuhan General Group CEO Jeff Robinson.

Michael sachar mentionned “I have observed the work of Jeff and his team, and I find it both exceptionally promising and inspiring. Everything from product formulation to packaging is done with conviction and passion. The food and beverage industry must evolve to help. alleviate today’s global health problems. I love that the WGG brands provide premium ingredients infused with CBD and medicinal mushrooms, while delivering exceptional products that meet a wide range of customer needs. I am honored and looking forward to being named CEO of the division and excited to take the company’s mission forward much further. “

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative medical research on plant cannabinoids and psilocybin that develops and markets a range of CBD and mushroom products under the direction of Dr. AnnaRx â„¢, Medspresso â„¢ and Marques Handcrafted Delights â„¢. Additionally, our psilocybin research and clinical trials are targeting new therapies that will help patients with alcohol dependence, mental illness, and cardiovascular disease. Our mission is to bring botanical medicine to the forefront by deploying the best scientific and medical practices, clinical research and emerging technologies. The company is listed on the NASDAQ over-the-counter notice board under the symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
Email: [email protected]
Follow us on twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio

Forward-looking statements:

Safe Harbor Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995 The forward-looking statements contained in this press release include the intention, beliefs or expectations of the Company and members of its management team with respect to the future business operations of the Company and the assumptions on which these statements are well founded. Potential investors are cautioned that these forward-looking statements are not guarantees of future performance, that they involve risks and uncertainties and that actual results may differ materially from those contemplated by these forward-looking statements. Factors that could cause these differences include, but are not limited to, inability to achieve expected sales during negotiation, lack of revenue growth, customer drop-outs, inability to achieve improvements in terms performance, efficiency and profitability; and unfavorable developments in litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common shares. Additional factors which could cause actual results to differ materially from those contemplated in this press release can also be found on the Company’s website. The Company assumes no responsibility for updating forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc

See the source version on accesswire.com:

About Mitchel McMillan

Check Also

Web3 technology company Reltime enters Southern African markets that could reach over $80 billion in revenue by 2025

Innovative and inclusive strategic partnership to empower people and businesses while accelerating and leading the …